JAG1 and Miyoshi myopathy: In addition, recent studies presented across European and international meetings (e.g., ISEV 2025)—such as the identification of circulating EV-isomiR networks predictive of therapy response, Jagged1/2-dependent EV-mediated Notch activation driving osteoclastogenesis and angiogenesis in the BM niche and multi-omic EV protein–miRNA biomarker panels for MM staging and daratumumab response monitoring further reinforce the emerging role of exosomes as minimally invasive, prognostic, and functional mediators in MM (Figure 6).